Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial

OP0023 Sarilumab for the treatment of moderate-to-severe rheumatoid arthritis: Results of a phase 2, randomized, double-blind, placebo-controlled, international study

(2014) T.W. Huizinga et al.   ANNALS OF THE RHEUMATIC DISEASES

FRI0020 Preclinical development of sarilumab, the first fully human monoclonal antibody (MAB) against IL-6r alpha: utilization and value of double humanized animal model

(2014) L.-H. Wang et al.   ANNALS OF THE RHEUMATIC DISEASES

SAT0117 Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of The IL-6 Receptor: Relationship Between Eular Responses and Change from Baseline of Selected Clinical Parameters

(2014) M. C. Genovese et al.   ANNALS OF THE RHEUMATIC DISEASES

SAT0136 Sarilumab, a Fully Human Mab Against IL-6R Alpha, Subcutaneously-Administered Shows Significant Improvement in Ra Patients as Early as 2 Weeks: A Time to Event Analysis for Acr50 and Eular Good Response

(2014) R. Fleischmann et al.   ANNALS OF THE RHEUMATIC DISEASES

AB0037 Evaluation of the binding kinetics and functional bioassay activity of sarilumab and tocilizumab to the human il-6 receptor (il-6r) alpha

(2014) A. Rafique et al.   ANNALS OF THE RHEUMATIC DISEASES

Changes in Lipoproteins Associated With Methotrexate Therapy or Combination Therapy in Early Rheumatoid Arthritis: Results From the Treatment of Early Rheumatoid Arthritis Trial

(2013) Iris Navarro-Millán et al.   ARTHRITIS AND RHEUMATISM

Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction

(2011) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Integrated safety in tocilizumab clinical trials

(2011) Michael H Schiff et al.   ARTHRITIS RESEARCH & THERAPY

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu

(2010) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

The role of Interleukin 6 in the pathophysiology of rheumatoid arthritis

(2010) Srinivasan Srirangan et al.   Therapeutic Advances in Musculoskeletal Disease

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

(2009) G. Jones et al.   ANNALS OF THE RHEUMATIC DISEASES

Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions

(2009) E Choy et al.   ANNALS OF THE RHEUMATIC DISEASES

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

(2008) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

(2008) Mark C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

(2008) N. Nishimoto et al.   BLOOD

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

(2008) Josef S Smolen et al.   LANCET